Safety of reRT with SBRT plus concurrent and adjuvant pembrolizumab in patients with recurrent or new second primary head and neck squamous cell cancer in a previously irradiated field: RTOG 3507 Foundation (KEYSTROKE)
Wong, S., Torres-Saavedra, P., Le, Q.T., Chung, C., Jang, S., Huq, M.S., Jordan, R., Clump, D.A., Blakaj, D.M., Straza, M.W., Koyfman, S.Volume:
106
Journal:
International Journal of Radiation Oncology*Biology*Physics
DOI:
10.1016/j.ijrobp.2020.02.010
Date:
April, 2020
File:
PDF, 390 KB
2020
File converter
More search results
More benefits 
